The First Step in Adoptive Cell Immunotherapeutics: Assuring Cell Delivery via Glycoengineering
Despite decades of intensive attention directed to creation of genetically altered cells (e.g., as in development of chimeric antigen receptor (CAR) T-cells) and/or to achieve requisite in vitro accumulation of desired immunologic effectors (e.g., elaboration of virus-specific T cells, expansion of...
Main Author: | Robert Sackstein |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.03084/full |
Similar Items
-
Staining of E-selectin ligands on paraffin-embedded sections of tumor tissue
by: Mylène A. Carrascal, et al.
Published: (2018-05-01) -
E-Selectin Ligands in the Human Mononuclear Phagocyte System: Implications for Infection, Inflammation, and Immunotherapy
by: Mariana Silva, et al.
Published: (2018-01-01) -
Selectins—The Two Dr. Jekyll and Mr. Hyde Faces of Adhesion Molecules—A Review
by: Igor Tvaroška, et al.
Published: (2020-06-01) -
Regulation of T Cell Trafficking by Enzymatic Synthesis of O-Glycans
by: Samuel J. Hobbs, et al.
Published: (2017-05-01) -
L1CAM as an E-selectin Ligand in Colon Cancer
by: Fanny M. Deschepper, et al.
Published: (2020-11-01)